SETDB1 as a cancer target: challenges and perspectives in drug design (2024)
Hassanie, Haifa 
; Penteado, André Berndt ; Almeida, Larissa Costa de ; Calil, Raisa Ludmila; Emery, Flavio da Silva ; Costa-Lotufo, Letícia Veras ; Trossini, Gustavo Henrique Goulart
Source: RSC Medicinal Chemistry. Unidades: FCFRP, ICB, FCF
Subjects: NEOPLASIAS, MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HASSANIE, Haifa et al. SETDB1 as a cancer target: challenges and perspectives in drug design. RSC Medicinal Chemistry, v. 15, n. 5, p. 1424-1451, 2024Tradução . . Disponível em: https://dx.doi.org/10.1039/D3MD00366C. Acesso em: 04 ago. 2024.APA
Hassanie, H., Penteado, A. B., Almeida, L. C. de, Calil, R. L., Emery, F. da S., Costa-Lotufo, L. V., & Trossini, G. H. G. (2024). SETDB1 as a cancer target: challenges and perspectives in drug design. RSC Medicinal Chemistry, 15( 5), 1424-1451. doi:10.1039/D3MD00366CNLM
Hassanie H, Penteado AB, Almeida LC de, Calil RL, Emery F da S, Costa-Lotufo LV, Trossini GHG. SETDB1 as a cancer target: challenges and perspectives in drug design [Internet]. RSC Medicinal Chemistry. 2024 ; 15( 5): 1424-1451.[citado 2024 ago. 04 ] Available from: https://dx.doi.org/10.1039/D3MD00366CVancouver
Hassanie H, Penteado AB, Almeida LC de, Calil RL, Emery F da S, Costa-Lotufo LV, Trossini GHG. SETDB1 as a cancer target: challenges and perspectives in drug design [Internet]. RSC Medicinal Chemistry. 2024 ; 15( 5): 1424-1451.[citado 2024 ago. 04 ] Available from: https://dx.doi.org/10.1039/D3MD00366C
